"The U.S. Food and Drug Administration today notified Ranbaxy Laboratories, Ltd., that it is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility in Toansa, India, for FDA-regulated drug product"...
There have been no reports of overdose with KALBITOR. HAE patients have received single doses up to 90 mg intravenously without evidence of dose-related toxicity.
Do not administer KALBITOR to a patient who has known clinical hypersensitivity to KALBITOR. [see WARNINGS AND PRECAUTIONS].
Last reviewed on RxList: 9/18/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Kalbitor Information
Report Problems to the Food and Drug Administration
Find out what women really need.